96 related articles for article (PubMed ID: 19616902)
1. Signal detection in post-marketing surveillance for controlled substances.
Dasgupta N; Schnoll SH
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S33-41. PubMed ID: 19616902
[TBL] [Abstract][Full Text] [Related]
2. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
3. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
4. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
5. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.
Lehman HP; Chen J; Gould AL; Kassekert R; Beninger PR; Carney R; Goldberg M; Goss MA; Kidos K; Sharrar RG; Shields K; Sweet A; Wiholm BE; Honig PK
Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922
[TBL] [Abstract][Full Text] [Related]
7. Automated support for pharmacovigilance: a proposed system.
Bright RA; Nelson RC
Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
[TBL] [Abstract][Full Text] [Related]
8. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
9. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in Europe and North America: divergent approaches.
Wiktorowicz M; Lexchin J; Moscou K
Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
[TBL] [Abstract][Full Text] [Related]
11. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing surveillance of licensed medicinal and other products.
Griffin JP
Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
[TBL] [Abstract][Full Text] [Related]
13. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
14. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
15. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
16. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
17. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
Hughes DA; Bayoumi AM; Pirmohamed M
Clin Pharmacol Ther; 2007 Aug; 82(2):123-7. PubMed ID: 17632534
[TBL] [Abstract][Full Text] [Related]
18. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data.
Rolka H; Bracy D; Russell C; Fram D; Ball R
Stat Med; 2005 Feb; 24(4):551-62. PubMed ID: 15678409
[TBL] [Abstract][Full Text] [Related]
19. Communicating the risks and benefits of medicines.
Schmid EF; Smith DA; Ryder SW
Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
[TBL] [Abstract][Full Text] [Related]
20. Early postmarketing drug safety surveillance: data mining points to consider.
Hauben M
Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
